In patients with psoriasis, treatment with tildrakizumab improved HRQOL and patient-reported symptoms in a real-world setting, according to a study published in the Journal of Dermatological Treatment. In a clinical trial of tildrakizumab, Neal Bhatia, MD, and colleagues evaluated clinical symptoms and changes in HRQOL in patients with psoriasis. Patients received tildrakizumab 100 mg at week (W) 0, W4, and every 12 weeks thereafter during a W28 interim analysis of a 64-week phase 4 study. Improvement from baseline in Dermatology Life Quality Index, Psychological General Well-Being Index (PGWBI), and Itch-, Pain-, and Scaling-Numerical Rating Scale scores through W28 were the end points. Of 55 patients enrolled, 53 were evaluated at W28. Mean (standard deviation [SD]) total PGWBI score improved from baseline to W28 (change, 3.7 [12.4]; P=0.033), as did the positive well-being (1.0 [2.9]; P=0.018) and general health (1.5 [2.2]; P<0.001) domain scores.
